Neumora Therapeutics, Inc.
NMRA
$1.28
-$0.12-8.57%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -3.33% | -89.07% | -108.25% | -105.71% | -80.23% |
| Total Depreciation and Amortization | -5.54% | -1.39% | 5.63% | 10.41% | 12.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -53.53% | 629.45% | 843.83% | 783.03% | 261.68% |
| Change in Net Operating Assets | 354.37% | 1,228.63% | -2,618.75% | -117.46% | -28.08% |
| Cash from Operations | -12.04% | -29.42% | -65.01% | -49.62% | -42.11% |
| Capital Expenditure | 100.00% | -753.13% | -352.91% | -130.73% | 77.10% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -209.38% | -0.09% | -352.88% | -10.55% | 138.51% |
| Cash from Investing | -209.58% | -1.78% | -356.63% | -11.11% | 138.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -90.86% | -97.21% | 20,011.07% | 7,570.35% | 8,787.55% |
| Repurchase of Common Stock | -- | 100.00% | 100.00% | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 64.66% | -1,107.21% | -807.66% | -312.13% |
| Cash from Financing | -90.69% | -97.86% | 106.32% | 101.11% | 100.39% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -274.29% | -185.50% | -279.85% | 64.69% | 179.59% |
